Femasys Attracts $8 Million in Funding

Femasys Inc. is planning to use the $8 million in recent financing to accelerate commercialization efforts and strengthen its ability to address significant unmet needs in women’s reproductive health.

“Ramping commercialization of our FemaSeed and FemBloc offerings remains our highest priority, and this financing enables us to execute on our strategy, achieve near-term milestones, strengthen our market presence, and accelerate toward meaningful revenue growth,” Femasys Founder/CEO Kathy Lee-Sepsick said. “We are especially grateful for the continued support of our two largest shareholders, including Jorey Chernett, whose belief in our mission affirms the long-term value we are creating for investors and the women we serve.”

Recent Femasys milestones announced since June include:

• Regulatory approvals of FemBloc non-surgical permanent birth control in Europe (June 25) and the United Kingdom (Aug. 20)
• Introduction of FemSperm Setup Kit, the first in the product family, enabling activation of FemaSeed, a first-step infertility treatment, in the gynecologist’s office (Aug. 21)
• First commercial entry into Europe with a $400,000 order for FemBloc in Spain (Aug. 6)
• Regulatory approval for FemaSeed in Australia and New Zealand (July 1)
• Appointment of a chief commercial officer to drive portfolio revenue growth (June 17)
• Partnership with Carolinas Fertility Institute, one of the nation’s top fertility clinics, to offer FemaSeed across its eight locations (June 11)

“FemBloc addresses a long overdue need in women’s health. My family experienced the greatest loss when my mother passed away during a tubal ligation surgery, which was the only option available to women for permanent contraception until FemBloc,” noted Jorey Chernett, founder/CEO of Clearpath, managing member of Pointillist Family Office, and Femasys’ largest shareholder. “No woman should ever die from an elective procedure, and FemBloc eliminates this risk. As a long-time healthcare executive and entrepreneur, I also recognize the important work Femasys is advancing in infertility care. Their FemaSeed product fills a critical void in the market and offers another groundbreaking option for women. I am honored to support this mission, and as an experienced investor, I am confident my commitment will help bring these transformative products to women while creating meaningful value for shareholders.”

Femasys is a biomedical innovator striving to make fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its patent-protected portfolio of in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the United States and key international markets. Femasys’ fertility portfolio includes FemaSeed Intratubal Insemination, a first-step infertility treatment; and FemVue, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrates FemaSeed is more than twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.¹

Alongside FemBloc, the FemChec diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.² For U.S. Food and Drug Administration approval, enrollment in the FINALE pivotal trial is on-going.

References
¹ Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.
² Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.